NAS10026,944+1.18%S&P7,385+0.42%GOLD$4,067−1.12%BTC$75,586−0.47%VIX25.28−10.29%latest tape · as of 18:01 UTC
The Screen · Industrials · Electrical Equipment & Parts
TGENTecogen Inc
TGEN · NYSE AMERICAN · USD · Market cap $58M · 119 employees
Tecogen Inc., together with its subsidiaries, designs, manufactures, markets, and maintains cogeneration products for multi-family residential, commercial, recreational, and industrial use in the United States.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.36, read 2026-10-29
Ethical passes the values gate
Price1.53 USD
Fair value1.11Our model only; the analyst targets sit too far from the price to cross-check it.
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-04Read Distribution1.88-18.6% to today ✓Markdown gives way to Distribution after a 38% slide in 7 weeks
2026-09-14Read Markdown3.05-49.8% to today ✓Accumulation gives way to Markdown after a 14% slide in 4 weeks
2026-08-14Read Accumulation3.55-56.9% to today Markup gives way to Accumulation after a 38% slide in 6 weeks
2026-07-02Read Markup5.73-73.3% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tecogen Inc holds its Distribution at $1.53. The statistical read favours the sellers, held for 38 days.
As held on the ledger · 2026-11-05
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 38 days
Price at the screen
$1.53
Valuation
N/A trailing · 12.80 forward price to earnings
Values screen
PASS· score 70.0
Beta
2.22
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.61%
Below 33%
Interest-bearing debt is just 7.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
45.18%
Below 49%
Money owed to the company is 45.2% of assets, under the 49% limit.
Pass
Revenue purity
0.56%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Tecogen clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TGEN's ethical verdict changes
Today TGEN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; the analyst targets sit too far from the price to cross-check it.
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $1.11 fair value estimate, none competitive moat.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 37.8% above the base estimate.
Third-party analyst targets. The average target sits +390% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $1.11, with a range of $1.11 to $1.95, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 12.8x forward earnings, the price already runs ahead of the business. It trades 55% above our $1.11 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TGEN trades on NYSE AMERICAN. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
2026-10-28Markdown$1.92-14.7%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
2026-10-21Markdown$2.25-7.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
2026-10-14Markdown$2.42-26.9%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 26.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9. Since the last review it dropped out of the Titan Ethical 500; its quality tier slipped to Watch; its composite score eased.
2026-10-02Markdown$3.31+8.5%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
2026-09-14Markdown · changed$3.05-14.1%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 38.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
2026-07-18Markup$5.73+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (3 analysts) rates it strong buy, with a mean price target of $9.
2026-07-03Markup$5.73+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$5.73Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.